Oxford Gene Technology (OGT), Oxford, UK, has developed a targeted next-generation sequencing (NGS) panel for constitutional cytogenetics research. The new CytoSure NGS panel will combine the strengths of microarrays and NGS to deliver a comprehensive all-in-one assay.
Used in conjunction with OGT’s Interpret analysis software, the new panel facilitates accurate detection of loss of heterozygosity (LOH), mosaicism, and copy-number variants (CNVs) in addition to the single-nucleotide variants (SNVs) and insertions/deletions (indels) more traditionally assayed by NGS.
With up-to-date content for intellectual disability (ID) and developmental delay (DD), the new targeted NGS panel and Interpret software enable users to detect even single-exon CNVs accurately.
“We have developed our CytoSure NGS panel to meet the increasing desire of labs to transition from microarrays to NGS and obtain as much information as possible from a single assay,” says Emma Shipstone, executive vice president of marketing at OGT. “NGS technologies have traditionally struggled with CNV detection, but thanks to OGT’s panel design expertise and advanced software algorithms, we have overcome these challenges, delivering exceptional CNV data that exhibits excellent concordance with arrays. The results are very easy to interpret, with our highly intuitive software allowing a seamless transition to NGS for ID/DD analysis, in what has historically been the domain of the array.”
“Moving with and anticipating market needs, we’re strengthening our CytoSure brand in constitutional cytogenetics with the development of our first CytoSure NGS panel,” says OGT CEO John Anson, PhD. “OGT, as a part of Sysmex, is committed to developing our assay portfolio, delivering the highest quality solutions to meet the real-world challenges faced by cytogeneticists. CytoSure NGS represents a real leap forward in NGS technology, demonstrating OGT’s capability—as experts in hybridization—to lead the global market in this field.”
CytoSure is for research use only. For more information, visit Oxford Gene Technology.